<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01880632</url>
  </required_header>
  <id_info>
    <org_study_id>ML28733</org_study_id>
    <nct_id>NCT01880632</nct_id>
  </id_info>
  <brief_title>Oxaliplatin Plus Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Adenocarcinoma</brief_title>
  <acronym>Neo-Classic</acronym>
  <official_title>A Multicenter, Single Arm, Open-label Trial of Oxaliplatin Plus Capecitabine (XELOX) in the Perioperative Treatment of Locally Advanced Gastric Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Target population:locally advanced gastric adenocarcinoma (LAGC, cT2~3/N+M0,or&#xD;
           cT4aN+M0);no previous chemo or radio therapy.&#xD;
&#xD;
        2. Primary objective:Response rate of XELOX in the neoadjuvant setting of LAGC.&#xD;
&#xD;
           Secondary objectives:&#xD;
&#xD;
             -  The progression free survival (PFS) in the perioperative treatment of locally&#xD;
                advanced gastric adenocarcinoma (cT3/N+M0,or cT4aN+M0);&#xD;
&#xD;
             -  percentage of pathological response ; percentage of grade 3 or 4 adverse events as&#xD;
                safety profile of perioperative treatments;&#xD;
&#xD;
             -  D2 resection -rate after neoadjuvant chemotherapy of XELOX;&#xD;
&#xD;
             -  Overall survival;&#xD;
&#xD;
             -  QOL during the whole period of treatment.&#xD;
&#xD;
        3. Trial design:This is a multicenter, single arm, open-label, phase II study to evaluate&#xD;
           the efficacy and safety of Oxaliplatin plus capecitabine(XELOX) in the perioperative&#xD;
           treatment of locally advanced gastric adenocarcinoma in combination with D2 resection.&#xD;
&#xD;
        4. Treatment plan:Patients will be given the perioperative chemotherapy as below once&#xD;
           recruited:Schedule of Oxaliplatin plus capecitabine (XELOX) will be as follow:&#xD;
           Capecitabine 1000 mg/m2 ，bid,d 1~14 every 3 weeks(treatment for 2 weeks and rest 1&#xD;
           week)Oxaliplatin：130mg/m2， iv infusion over 2h，d1,every 3 weeks.&#xD;
&#xD;
        5. Number of subjects:50 patients.Number of centers 5 sites, which have the high volume of&#xD;
           gastric operations in China, more than 500 per year.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Disease specific inclusion criteria:&#xD;
&#xD;
             -  Histologically documented gastricadenocarcinoma with Lauren classification&#xD;
                Clinically diagnosed stage T2-3/N+M0,orT4aN+M0 according to CT/MRI scan, and&#xD;
                resectable&#xD;
&#xD;
             -  Measurable disease is required&#xD;
&#xD;
             -  Karnofsky score 80%.&#xD;
&#xD;
             -  Physical condition and adequate organ function to ensure the success of abdominal&#xD;
                surgery.&#xD;
&#xD;
             -  Life expectancy ≥12 weeks.&#xD;
&#xD;
             -  Adequate hematological function: Neutrophil count ≥ 1.5 × 109/L, Platelets ≥ 100 ×&#xD;
                109/L and Hemoglobin ≥8g/dL .Adequate liver function: Total bilirubin ≤ 1.5 × upper&#xD;
                limit of normal (ULN); AST (SGOT) and ALT (SGPT) &lt; 2.5 × ULN in the absence of&#xD;
                liver metastases, or &lt; 5 × ULN in case of liver metastases. ALP ≤ 2.5 × upper limit&#xD;
                of normal (ULN); ALB ≥30g/L.&#xD;
&#xD;
           Adequate renal function: Serum creatinine ≤ 1.25 x ULN, and creatinine clearance ≥ 60&#xD;
           ml/min.&#xD;
&#xD;
             -  Female subjects should not be pregnant or breast-feeding.&#xD;
&#xD;
             -  No serious concomitant disease that will threaten the survival of patients to less&#xD;
                than 5 years.&#xD;
&#xD;
        2. General inclusion criteria:&#xD;
&#xD;
             -  Male or female. Age ≥ 18 years and ≤75 years&#xD;
&#xD;
             -  Written (signed) informed consent.&#xD;
&#xD;
             -  Able to comply with study and follow-up procedures.&#xD;
&#xD;
             -  Good compliance with the treatment plan。&#xD;
&#xD;
             -  Consent to provide tissue sample。&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the response rate of XELOX in the neoadjuvant setting of LAGC</measure>
    <time_frame>6 months after the last subject participating in</time_frame>
    <description>the response rate evaluation will be based on tumor assessment with follow-up, including chest and upper-abdominal During preoperative treatment period, CT scan will be performed every 6 -8 weeks (2 cycles after)., brain MRI and bone scan (ECT) will be performed if any suspected symptoms occur.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the progression free survival (PFS) in the perioperative treatment of locally advanced gastric adenocarcinoma (cT2-3/N+M0,or cT4aN+M0)</measure>
    <time_frame>42 months after the last subject participating in</time_frame>
    <description>progression by the evidence of CT/MRI scan at each evaluation at neoadjuvant period or follow-up time after surgery；During preoperative treatment period, CT scan will be performed every 6 -8 weeks (2 cycles after).After syrgery, CT scan will be planned every 6 months, brain MRI and bone scan (ECT) will be performed if any suspected symptoms occur.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percentage of pathological response</measure>
    <time_frame>10 months after the last subject participating in</time_frame>
    <description>After surgery，the pathological response will be measured by the pathologist for every Operation patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of grade 3 or 4 adverse events as safety profile of perioperative treatments</measure>
    <time_frame>1 month after the last date of treatment</time_frame>
    <description>Adverse events and clinical laboratory tests will be recorded by CTCAE (version 4.0) during the whole treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years after the last subject participating in</time_frame>
    <description>During the OS follow-up, out-patient clinic and telephone visit will be done every 3 months for the first two years, and every 6 months after two years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QOL during the whole period of treatment</measure>
    <time_frame>1 years after the last date of treatment</time_frame>
    <description>These assessment will be evaluated at every evaluation.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Gastric Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>XELOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clinically diagnosed stage T2-3/N+M0,orT4aN+M0 according to CT/MRI scan, and resectable</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XELOX</intervention_name>
    <description>Patients will be given the perioperative chemotherapy as below once recruited:&#xD;
Capecitabine ：500 mg tablets（Roche） Oxaliplatin：50mg/10ml（according to daily practice in each center）&#xD;
Schedule of Oxaliplatin plus capecitabine (XELOX) will be as follow:&#xD;
Capecitabine 1000 mg/m2 ，orally taken 30 minutes after meal, bid ， d 1~14 every 3 weeks(treatment for 2 weeks and rest 1 week) Oxaliplatin：130mg/m2， iv infusion over 2h，d1,every 3 weeks</description>
    <arm_group_label>XELOX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically documented gastricadenocarcinoma with Lauren classification Clinically&#xD;
             diagnosed stage T2-3/N+M0,orT4aN+M0 according to CT/MRI scan, and resectable&#xD;
&#xD;
          -  Measurable disease is required&#xD;
&#xD;
          -  Karnofsky score 80%.&#xD;
&#xD;
          -  Physical condition and adequate organ function to ensure the success of abdominal&#xD;
             surgery.&#xD;
&#xD;
          -  Life expectancy ≥12 weeks.&#xD;
&#xD;
          -  Adequate hematological function: Neutrophil count ≥ 1.5 × 109/L, Platelets ≥ 100 ×&#xD;
             109/L and Hemoglobin ≥8g/dL .Adequate liver function: Total bilirubin ≤ 1.5 × upper&#xD;
             limit of normal (ULN); AST (SGOT) and ALT (SGPT) &lt; 2.5 × ULN in the absence of liver&#xD;
             metastases, or &lt; 5 × ULN in case of liver metastases. ALP ≤ 2.5 × upper limit of&#xD;
             normal (ULN); ALB ≥30g/L.Adequate renal function: Serum creatinine ≤ 1.25 x ULN, and&#xD;
             creatinine clearance ≥ 60 ml/min.&#xD;
&#xD;
          -  Female subjects should not be pregnant or breast-feeding.&#xD;
&#xD;
          -  No serious concomitant disease that will threaten the survival of patients to less&#xD;
             than 5 years.&#xD;
&#xD;
          -  Male or female.&#xD;
&#xD;
          -  Age ≥ 18 years and ≤75 years&#xD;
&#xD;
          -  Written (signed) informed consent.&#xD;
&#xD;
          -  Able to comply with study and follow-up procedures.&#xD;
&#xD;
          -  Good compliance with the treatment plan.&#xD;
&#xD;
          -  Consent to provide tissue sample.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating (in case of potentially childbearing woman, pregnancy test is&#xD;
             positive)&#xD;
&#xD;
          -  Patients of child-bearing age or the potential to father a child who refuse to use&#xD;
             adequate contraception&#xD;
&#xD;
          -  Serious concomitant disorders that would compromise the safety of the patient or&#xD;
             compromise the patient's ability to complete the study, at the discretion of the&#xD;
             investigator.&#xD;
&#xD;
          -  History of another malignancy in the last 5 years with the exception of the following:&#xD;
&#xD;
        Any previous palliative, adjuvant or neoadjuvant chemotherapy and/or radiotherapy. Prior&#xD;
        treatment for locally advanced or metastatic gastric cancer. Any metastatic disease will&#xD;
        render patient ineligible according to AJCC staging manual.&#xD;
&#xD;
          -  Distant metastases (M1) including distant nodal Groups (peripancreatic, para-aortic,&#xD;
             portal, retroperitoneal, mesenteric node, by CT/MRI, or PET/CT&#xD;
&#xD;
          -  Treatment within the last 30 days with any investigational drug. Concurrent&#xD;
             administration of any other cancer therapy, including cytotoxic chemotherapy, hormonal&#xD;
             therapy, and immunotherapy.&#xD;
&#xD;
          -  Active infection that in the opinion of the investigator would compromise the&#xD;
             patient's ability to tolerate therapy.&#xD;
&#xD;
          -  Poorly controlled diabetes mellitus with fasting blood sugar &gt; 18 mM. Second primary&#xD;
             malignancy that is clinically detectable at the time of consideration for study&#xD;
             enrollment.&#xD;
&#xD;
          -  History of significant neurological or mental disorder, including seizures or&#xD;
             dementia, which would interfere compliance and sign of consent inform. any history of&#xD;
             hypersensitivity to 5-fluorouracil or platinum and other investigational drug&#xD;
&#xD;
          -  Ileus, chronic inflammatory intestinal disease or extensive resection of the small&#xD;
             intestine and other disorders which limit drug reabsorption. This includes gastric&#xD;
             dumping syndrome, indications of accelerated passage through the small intestine,&#xD;
             indications of reabsorption disorders after intestinal surgery&#xD;
&#xD;
          -  Unstable, persistent cardiac disease despite medicinal treatment, myocardial&#xD;
             infarction within 6 months before the start of the trial&#xD;
&#xD;
          -  Organ transplant patient need immunosuppression treatment.&#xD;
&#xD;
          -  Previous surgery on primary tumour; Prior palliative surgery (open and closure,&#xD;
             passage operation)&#xD;
&#xD;
          -  Any other type of tumour (e.g. leiomyosarcoma, lymphoma) or a secondary malignancy,&#xD;
             excepting basal cell skin carcinoma or basal cell carcinoma in situ of the cervix&#xD;
             which have already been successfully treated&#xD;
&#xD;
          -  Symptomatic peripheral neuropathy NCI CTC version&gt; 3.0 grade.&#xD;
&#xD;
          -  Patients under anticoagulant therapy with warfarin or other coumarines are excluded&#xD;
             from participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tianshu Liu, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical oncology Shanghai zhongshan hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tianshu Liu, Doctor</last_name>
    <phone>+861368 1973 996</phone>
    <email>liu.tianshu@zs-hospital.sh.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongshan Hospital Affiliated to Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tianshu Liu, doctor</last_name>
      <email>liu.tianshu@zs-hospital.sh.cn</email>
    </contact>
    <investigator>
      <last_name>Yiyi yu, Master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>June 8, 2013</study_first_submitted>
  <study_first_submitted_qc>June 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2013</study_first_posted>
  <last_update_submitted>December 17, 2015</last_update_submitted>
  <last_update_submitted_qc>December 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Zhongshan Hospital</investigator_affiliation>
    <investigator_full_name>Tianshu Liu</investigator_full_name>
    <investigator_title>Director of Medical oncology derpartment</investigator_title>
  </responsible_party>
  <keyword>XELOX</keyword>
  <keyword>perioperative treatment</keyword>
  <keyword>locally advanced gastric adenocarcinoma</keyword>
  <keyword>D2 resection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

